Applicable to all London trusts providing cancer services.
Benefits of the contract
LPP is currently monitoring the uptake of biosimilar trastuzumab and the cost savings achieved within London due to this change. The volumes are taken from IQVIA and Define databases. The contract is owned by the Commercial Medicines Unit.